Standard BioTools Inc (LAB) Outlook Starting To Look Brighter?

Standard BioTools Inc (LAB) concluded trading on Wednesday at a closing price of $2.66, with 3.91 million shares of worth about $10.4 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -2.56% during that period and on April 3, 2024 the price saw a gain of about 0.76%. Currently the company’s common shares owned by public are about 290.12M shares, out of which, 282.68M shares are available for trading.

Stock saw a price change of 0.76% in past 5 days and over the past one month there was a price change of 3.10%. Year-to-date (YTD), LAB shares are showing a performance of 20.36% which increased to 36.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.46 but also hit the highest price of $3.16 during that period. The average intraday trading volume for Standard BioTools Inc shares is 1.94 million. The stock is currently trading 0.06% above its 20-day simple moving average (SMA20), while that difference is up 6.42% for SMA50 and it goes to 12.25% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Standard BioTools Inc (NASDAQ: LAB) currently have 290.12M outstanding shares and institutions hold larger chunk of about 63.79% of that.

The stock has a current market capitalization of $771.72M and its 3Y-monthly beta is at 1.64. It has posted earnings per share of -$0.94 in the same period. It has Quick Ratio of 1.26 while making debt-to-equity ratio of 0.60. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LAB, volatility over the week remained 4.87% while standing at 5.15% over the month.

Stock’s fiscal year EPS is expected to rise by 54.26% while it is estimated to increase by 58.14% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by KeyBanc Capital Markets on July 12, 2023 offering an Overweight rating for the stock and assigned a target price of $4 to it.

Most Popular

Related Posts